SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is surging after a preliminary business update revealed record-breaking demand with over $60 billion in new orders and a significant doubling of gross margin guidance. The community is actively debating the potential for a massive short squeeze, with many pointing to the company's strong backlog and improved profitability as evidence that the stock remains deeply undervalued despite persistent skepticism regarding management and legal concerns.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

AT&T shares are currently experiencing significant volatility as investors weigh robust quarterly results, including record fiber and wireless additions, against broader market concerns regarding potential long-term competition from Starlink. The community remains focused on the company's foundational role in AI infrastructure and its commitment to consistent dividend payouts, while actively debating whether recent price declines represent an oversold buying opportunity.

GE Vernova, Inc. engages in the electric power industry. It operates through the following segments: Power, Wind, and Electrification. The Power segment offers design, manufacture, and servicing gas, nuclear, hydro, and steam technologies, providing a critical foundation of dispatchable, flexible, stable, and reliable power. The Wind segment manages wind generation technologies, including onshore and offshore wind turbines and blades. The Electrification segment refers to the grid solutions, power conversion, electrification software, and solar and storage solutions technologies required for the transmission, distribution, conversion, storage, and orchestration of electricity from point of generation to point of consumption. The company was founded November 9, 2021 and is headquartered in Cambridge, MA.

GE Vernova Inc.

GE Vernova is drawing significant investor interest following strong earnings and a raised financial outlook, fueled by massive backlog growth and surging electrification demand for AI data centers. While some market participants are taking profits due to valuation concerns, the community remains heavily focused on the company's long-term potential as a critical player in global power infrastructure.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is facing a sell-off as investors react to reports of delays in its Gemini 3.5 Pro model rollout, raising concerns about Google's pace in the competitive AI race. Despite the short-term volatility, the community remains divided between those viewing the pullback as a buying opportunity in a fundamental powerhouse and those wary of the high expectations surrounding AI capital expenditure.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals is capturing market attention as the company moves toward Phase 3 data for its plozasiran program in severe hypertriglyceridemia, with the community closely tracking the potential for label expansion and long-term pipeline value. Investors are actively discussing the firm's strategic positioning in the obesity and CNS markets, while navigating volatility driven by index rebalancing and institutional trading patterns.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is seeing significant volatility as market participants debate its long-term valuation and dependency on AI-related search traffic. Community discussions are split between bearish sentiment over potential content licensing disputes and bullish technical setups centered around the stock's role in the evolving AI and digital advertising landscape.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is trending as investors aggressively monitor its capital expenditure and AI infrastructure development ahead of upcoming earnings, with sentiment split between concerns over Gemini's performance delays and enthusiasm for the stock's long-term dominance in search and cloud computing. The community is actively debating whether high spending on AI will yield immediate monetization or if Alphabet's massive investment cycle signals a broader shift in market volatility.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is trending as investors digest the finalization of a multi-year partnership with Virgin Atlantic to launch electric air taxi services in the UK, a development that follows consistent gains and strong volume. Community sentiment remains divided between bulls focused on the company's long-term certification milestones and strategic manufacturing alliance with Toyota, and bears skeptical of high cash burn and potential dilution.

Fluence Energy, Inc. engages in energy storage products and services, and artificial intelligence-enabled digital applications for renewables and storage. Its storage includes Smartstack, Gridstack Pro, Grisdtack, and Ultrastack. The company was founded on June 21, 2021, and is headquartered in Arlington, VA.

Fluence Energy Inc - Ordinary Shares - Class A

Fluence Energy (FLNC) is trending as investors weigh an analyst upgrade from Citi, which highlights its role in the energy storage and AI-driven infrastructure buildout, against a volatile technical backdrop characterized by recent insider selling and price sensitivity. The community remains actively engaged in debating the company's long-term growth potential versus its near-term profitability challenges, with many traders closely monitoring support levels and looking for confirmation of further hyperscaler partnerships.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is currently the focus of significant community interest as investors await the upcoming ASCO plenary presentation of late-breaking Phase III overall survival data for its bispecific antibody, ivonescimab. Despite recent analyst skepticism and price volatility, shareholders remain heavily focused on the drug's potential to challenge existing standards of care and the company's high-stakes regulatory milestones later this year.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cognition Therapeutics Gets Positive FDA Feedback Over Phase 3 Study Of DLB Psychosis – But CGTX Stock Just Crashed 33%

Equity

The company reported that the U.S. Food and Drug Administration aligned with the company on several key aspects of the Phase 3 study, which is expected to begin in mid-2027.

Cognition Therapeutics (CGTX) to Release Earnings on Wednesday

Cognition Therapeutics (NASDAQ:CGTX) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-6-cognition-therapeutics-inc-stock...

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Recommendation of "Moderate Buy" by Analysts

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) has received a consensus rating of "Moderate Buy" from the four analysts that are covering the firm, MarketBeat reports. One research...

Insider Buying: Cognition Therapeutics (NASDAQ:CGTX) CEO Acquires 9,175 Shares of Stock

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) CEO Lisa Ricciardi bought 9,175 shares of the company's stock in a transaction dated Thursday, April 16th. The shares were acquired at an...

John Brendan Doyle Purchases 10,000 Shares of Cognition Therapeutics (NASDAQ:CGTX) Stock

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) CFO John Brendan Doyle bought 10,000 shares of the stock in a transaction that occurred on Thursday, April 16th. The shares were bought at an average cost of $1.13 per share, with a total value of $11,300.00. Following the completion of...

Lisa Ricciardi Acquires 9,175 Shares of Cognition Therapeutics (NASDAQ:CGTX) Stock

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) CEO Lisa Ricciardi acquired 9,175 shares of the business's stock in a transaction that occurred on Thursday, April 16th. The shares were purchased at an average price of $1.10 per share, with a total value of $10,092.50. Following the...

Cognition Therapeutics Targets Faster DLB Psychosis Path as Zervimesine Nears Late-Stage Plans

Cognition Therapeutics (NASDAQ:CGTX) executives told investors at the Needham conference that the company is preparing to advance its once-daily oral candidate zervimesine into late-stage...

Q1 Earnings Forecast for CGTX Issued By HC Wainwright

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Free Report) - HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for Cognition Therapeutics in a research report issued on Friday...

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Rating of "Moderate Buy" by Brokerages

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) has been assigned an average rating of "Moderate Buy" from the four research firms that are covering the stock, MarketBeat reports. One...

Cognition Therapeutics (NASDAQ:CGTX) Receives Buy Rating from Chardan Capital

Chardan Capital restated a "buy" rating and set a $4.00 target price on shares of Cognition Therapeutics in a research report on Friday...

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. It offers the CT1812 which aims to restore the damaged cellular processes that drive diseases such as Alzheimer’s disease, dry age-related macular degeneration, geographic atrophy and other conditions. The company was founded by Franz F. Hefti, Gilbert M. Rishton, and Susan M. Catalano on August 21, 2007 and is headquartered in Purchase, NY.

Cognition Therapeutics Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

CGTXCognition Therapeutics Inc

Fundamentals

Latest CGTX News